Our Approach:
Identify diseases with mTOR pathway genomic alterations and strong evidence of mTOR involvement in pathology of disease
Target genomically defined subgroups across cancer types with mTOR pathway alterations (e.g., TSC1, TSC2) who are most likely to respond to mTOR treatment
Treat patients with FYARRO™ (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus, ABI-009)